ClinicalTrials.gg
Not yet recruitingNCT07861100AMBIENCEUpdated Oct 6, 2026

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

A Phase 3 interventional study of Zenagamtide and Placebo in Cardiovascular Risk and Obesity, sponsored by Novo Nordisk A/S. Not yet recruiting at 769 sites in 26 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8,500
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing zenagamtide in Obesity — 17 open to participants now, 20 under way, 14 of them phase 3. zenagamtide · Obesity.

Planned enrollment
Largest of 24
8,500 · median 360
Started
2026
with 18 others
Phase 3
14 of 24
11 open now
Primary completion
2030-09
later than 19 of 19 live
Registered
23rd of 24
by date
Lead sponsor
24 of 24
Novo Nordisk A/S

Among the 24 studies testing zenagamtide in Obesity, this one has the largest planned enrollment, is one of 19 that started in 2026, is one of 14 in phase 3, reaches primary completion later than 19 of the 19 other live ones, and was the 23rd registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

Browse Obesity studies →

Open to participants now

17 of the 24 studies testing zenagamtide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About zenagamtide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing zenagamtide in Obesity, or all of them as a file.
02

Study summary

This clinical study is being conducted to evaluate the safety and effectiveness of zenagamtide in people with atherosclerotic cardiovascular disease (ASCVD) and excess body weight compared with placebo. The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have ASCVD and excess body weight. Participants will be randomly assigned by chance to receive either zenagamtide, the investigational treatment being tested, or a placebo, which contains no active medicine. Half of the participants will receive zenagamtide, and treatment assignment will be determined randomly. Zenagamtide is a new investigational medicine that is not yet available for prescription by doctors.

03

Conditions studied

  • Cardiovascular Risk
  • Obesity

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Established ASCVD is defined as at least one of the below conditions (a-c):

    a. Prior myocardial infarction (MI) b. Symptomatic peripheral artery disease (PAD) defined as at least one of the following: i. Intermittent claudication with an ankle-brachial index (ABI) less than (\<) 0.85 at rest ii. Lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g. trauma or osteomyelitis) c. Cerebrovascular disease defined as the following: i. Prior stroke

  • Participants with Type 2 Diabetes (T2D) (at screening) are allowed in the study with the following provisions:

    1. Treatment should be stable for greater than or equal to (≥) 90 days before screening as assessed by the investigator.
    2. Glucose lowering agents are permitted according to local label except glucagon-like peptide-1 receptor agonist (GLP-1 RA), glucose-dependent insulinotropic polypeptide (GIP) and amylin analogues; for insulins, only basal insulin is allowed.

Exclusion criteria

Exclusion Criteria:

  • MI, stroke, unstable angina pectoris, or worsening heart failure (HF) leading to either hospitalization or intravenous loop diuretics within 30 days prior to the day of screening and until randomization.
  • Coronary, carotid, or peripheral artery revascularization or percutaneous valve repair or replacement within 30 days prior to the day of screening or planned during the study period and known at screening.
  • Chronic heart failure classified at screening.
  • Glycaemia-related:

    1. Recurrent severe hypoglycaemic episodes within the last year as judged by the investigator.
    2. Known history of hypoglycaemia unawareness as indicated by the investigator according to Clarke's questionnaire question 8.
    3. History of type 1 diabetes (T1D).
    4. Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or who, at the time of screening, are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
    5. (HbA1c) greater than (>) 10 percentage (%) (86 millimoles per mole [mmol/mol]) as measured by central laboratory at screening.
  • General health and safety:

    1. Treatment with any GLP-1 RA, GIP RA or amylin analogue for any indication before screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
8,500 participants (estimated)

Study arms

  • Experimental
    Zenagamtide

    Participants will receive zenagamtide subcutaneously (s.c.) in a dose escalating manner once weekly.

    Drug: Zenagamtide

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to zenagamtide s.c. once weekly.

    Drug: Placebo

Interventions

  • Zenagamtide will be administered subcutaneously.

  • DrugPlacebo

    Placebo will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Time from randomization to first occurrence of a 4-point (P) composite major adverse cardiovascular events (MACE) endpoint consisting of: Cardiovascular (CV) death, Non-fatal MI, Non-fatal stroke, HF hospitalization or urgent HF visit

    Measured in days.

    Time frame: From baseline (week 0) to up to 203 weeks or longer

Secondary outcomes

  1. Time from randomization to first occurrence of an expanded 5-P composite MACE endpoint consisting of: All-cause death, Non-fatal MI, Non-fatal stroke, HF hospitalization or urgent HF visit, Coronary revascularization

    Measured in days.

    Time frame: From baseline (week 0) to up to 203 weeks or longer

  2. Time from randomization to first occurrence of a 3-P composite MACE endpoint consisting of: CV death, Non-fatal MI, Non-fatal stroke

    Measured in days.

    Time frame: From baseline (week 0) to up to 203 weeks or longer

  3. Change in Estimated Glomerular Filtration Rate (eGFR) (creatinine and cystatin C-based Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] 2021) for participants with baseline eGFR< 60 millilitre per minute per 1.73 square metre (mL/min/1.73 m^2)

    Measured as mL/min/1.73 m\^2.

    Time frame: From baseline (week 0) to week 104

  4. Time from randomization to all-cause death

    Measured in days.

    Time frame: From baseline (week 0) to up to 203 weeks or longer

  5. Time from randomization to CV death

    Measured in days.

    Time frame: From baseline (week 0) to up to 203 weeks or longer

07

Study locations

769 sites

Showing the first 100 of 769 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Sep 2030, 46 months later.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 46 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartEst.
Oct 26, 2026
Primary completionEst.
Sep 16, 2030
CompletionEst.
Sep 16, 2030
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861100
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Oct 26, 2026 (estimated)
Primary completion
Sep 16, 2030 (estimated)
Completion
Sep 16, 2030 (estimated)
Last update
Oct 6, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zenagamtide

Start the discussion